A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Peptide-YY-Novo-Nordisk (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 10 Feb 2017 Status changed from recruiting to completed.
- 31 May 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
- 31 May 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.